EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:71245 - asenapine maleate
| ChEBI ID | CHEBI:71245 |
| ChEBI Name | asenapine maleate |
| Stars | |
| Definition | A racemate consisting of equal amounts of (R,R)- and (S,S)-asenapine maleate. Used for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features. |
| Last Modified | 27 November 2012 |
| Submitter | Steve |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | dopaminergic antagonist A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. alpha-adrenergic antagonist An agent that binds to but does not activate α-adrenergic receptors thereby blocking the actions of endogenous or exogenous α-adrenergic agonists. α-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. beta-adrenergic antagonist An agent that binds to but does not activate β-adrenergic receptors thereby blocking the actions of endogenous or exogenous β-adrenergic agonists. β-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety. serotonergic antagonist Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. |
| Applications: | dopaminergic antagonist A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. psychotropic drug A loosely defined grouping of drugs that have effects on psychological function. alpha-adrenergic antagonist An agent that binds to but does not activate α-adrenergic receptors thereby blocking the actions of endogenous or exogenous α-adrenergic agonists. α-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. second generation antipsychotic Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements. beta-adrenergic antagonist An agent that binds to but does not activate β-adrenergic receptors thereby blocking the actions of endogenous or exogenous β-adrenergic agonists. β-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety. serotonergic antagonist Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| asenapine maleate (CHEBI:71245) has part (R,R)-asenapine maleate (CHEBI:71246) |
| asenapine maleate (CHEBI:71245) has part (S,S)-asenapine maleate (CHEBI:71248) |
| asenapine maleate (CHEBI:71245) has part asenapine(1+) (CHEBI:71249) |
| asenapine maleate (CHEBI:71245) has role dopaminergic antagonist (CHEBI:48561) |
| asenapine maleate (CHEBI:71245) has role psychotropic drug (CHEBI:35471) |
| asenapine maleate (CHEBI:71245) has role second generation antipsychotic (CHEBI:65191) |
| asenapine maleate (CHEBI:71245) has role serotonergic antagonist (CHEBI:48279) |
| asenapine maleate (CHEBI:71245) has role α-adrenergic antagonist (CHEBI:37890) |
| asenapine maleate (CHEBI:71245) has role β-adrenergic antagonist (CHEBI:35530) |
| asenapine maleate (CHEBI:71245) is a racemate (CHEBI:60911) |
| IUPAC Names |
|---|
| rac-(3aR,12bR)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-but-2-enedioate |
| rac-(3aR,12bR)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-2-ium (2Z)-3-prop-2-enoate |
| Synonyms | Source |
|---|---|
| trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate | ChemIDplus |
| (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo(2,3:6,7)oxepino(4,5-c)pyrrole (2Z)-2-butenedioate | ChemIDplus |
| (3aRS,12bRS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-2-ium (2Z)-3-prop-2-enoate | ChEBI |
| (3aRS,12bRS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-but-2-enedioate | ChEBI |
| (±)-asenapine maleate | ChEBI |
| Brand Name | Source |
|---|---|
| Saphris | KEGG DRUG |
| Manual Xrefs | Databases |
|---|---|
| D02995 | KEGG DRUG |
| Asenapine | Wikipedia |
| WO2011159903 | Patent |
| NZ562124 | Patent |
| ZA200708493 | Patent |
| EP1917267 | Patent |
| KR20080005253 | Patent |
| Registry Numbers | Sources |
|---|---|
| Reaxys:3647286 | Reaxys |
| CAS:85650-56-2 | KEGG DRUG |
| CAS:85650-56-2 | ChemIDplus |
| Citations |
|---|